氯诺昔康治疗类风湿关节炎的疗效与安全性长期研究
[Long term study on the efficacy and safety of lornoxicam in rheumatoid arthritis].
作者信息
Frizziero L, Focherini M C, Valentini M, Reta M, Rocchi P
机构信息
Unità Operativa di Reumatologia, Ospedale Maggiore, Bologna, Italy.
出版信息
Minerva Med. 2002 Aug;93(4):315-20.
BACKGROUND
To assess the long term safety and therapeutic action of lornoxicam, a new non steroidal anti-inflammatory agent, in rheumatoid arthritis.
METHODS
Open trial was carried out on different dosage schedules of lornoxicam (4 or 8 mg bid and 4mg tid) administered for six to twelve months. Patients of both sexes were enrolled, with classical or definite rheumatoid arthritis according to the A.R.A. criteria.
RESULTS
Thirty-four patients (28 F, 6 M) were admitted, mean age (+/- SD) 53.9+/-14.2 years, mean duration of illness 9.2+/-10.7 years. Lornoxicam 8-16 mg/day showed good safety and therapeutic activity in long term treatment. Clinical improvement was limited, but progression of the disease was controlled. No adverse events were complained.
CONCLUSIONS
Lornoxicam presented a worth-while therapeutic action and a good tolerability in rheumatoid arthritis long term treatment.
背景
评估新型非甾体抗炎药氯诺昔康在类风湿性关节炎中的长期安全性及治疗作用。
方法
对服用氯诺昔康（4或8毫克，每日两次及4毫克，每日三次）不同剂量方案达6至12个月的患者进行开放性试验。纳入符合美国风湿病学会（A.R.A.）标准的典型或确诊类风湿性关节炎的男女患者。
结果
共收治34例患者（28例女性，6例男性），平均年龄（±标准差）53.9±14.2岁，平均病程9.2±10.7年。氯诺昔康8 - 16毫克/天在长期治疗中显示出良好的安全性及治疗活性。临床改善有限，但疾病进展得到控制。未出现不良事件报告。
结论
氯诺昔康在类风湿性关节炎的长期治疗中具有值得肯定的治疗作用及良好的耐受性。
Zotero 插件